CSF1R and central nervous system cancer: validated that the combination of CSF1R antibody 2G2 and PD-1 antibody altered the immune profile in tissues; particularly, it increased T cell infiltration and the ratios of CD8/CD4 and prolonged survival of mice with glioma (113).